凤凰网首页 手机凤凰网

凤凰卫视
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
免费注册
海普瑞(002399)公告正文

海普瑞:2014年第三季度报告全文

公告日期 2014-10-30
股票简称:海普瑞 股票代码:002399
                深圳市海普瑞药业股份有限公司 2014 年第三季度报告全文深圳市海普瑞药业股份有限公司
    2014 年第三季度报告
        2014 年 10 月
                                                   深圳市海普瑞药业股份有限公司 2014 年第三季度报告全文
                                   第一节 重要提示
    公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整,不存在虚假记载、误导性陈述或者重大遗漏,并承担个别和连带的法律责任。
    所有董事均已出席了审议本次季报的董事会会议。
    公司负责人李锂、主管会计工作负责人孔芸及会计机构负责人(会计主管人员)孔芸声明:保证季度报告中财务报表的真实、准确、完整。
                                                            深圳市海普瑞药业股份有限公司 2014 年第三季度报告全文
                             第二节 主要财务数据及股东变化一、主要会计数据和财务指标公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据□ 是 √ 否
                                       本报告期末                    上年度末              本报告期末比上年度末增减
    总资产(元)                            9,549,464,315.08              8,271,379,204.50                         15.45%归属于上市公司股东的净资产
                                        8,134,932,977.26              7,986,056,392.22                          1.86%(元)
                                                     本报告期比上年同期                            年初至报告期末比上
                                  本报告期                                    年初至报告期末
                                                            增减                                       年同期增减
    营业收入(元)                    523,698,923.89                   85.27%      1,434,840,528.99                16.70%归属于上市公司股东的净利润
                                  114,051,103.59                  176.06%        224,081,594.35               -23.15%(元)归属于上市公司股东的扣除非经
                                  113,151,748.14                  194.60%        221,202,683.49               -23.19%常性损益的净利润(元)经营活动产生的现金流量净额
                                        --                   --                  721,110,135.47                73.26%(元)
    基本每股收益(元/股)                         0.14                180.00%                   0.28              -22.22%
    稀释每股收益(元/股)                         0.14                180.00%                   0.28              -22.22%
    加权平均净资产收益率                         1.42%                 0.89%                   2.78%               -0.88%非经常性损益项目和金额√ 适用 □ 不适用
                                                                                                               单位:元
                         项目                               年初至报告期期末金额                      说明
    非流动资产处置损益(包括已计提资产减值准备的冲销部分)                       -135,154.45计入当期损益的政府补助(与企业业务密切相关,按照国家统
                                                                            2,337,323.63一标准定额或定量享受的政府补助除外)除同公司正常经营业务相关的有效套期保值业务外,持有交易性金融资产、交易性金融负债产生的公允价值变动损益,以及
                                                                            1,293,773.63处置交易性金融资产、交易性金融负债和可供出售金融资产取得的投资收益
    除上述各项之外的其他营业外收入和支出                                          -70,400.81
    减:所得税影响额                                                             402,930.27
    少数股东权益影响额(税后)                                              143,700.87
                                                          深圳市海普瑞药业股份有限公司 2014 年第三季度报告全文
    合计                                                                   2,878,910.86                  --对公司根据《公开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》定义界定的非经常性损益项目,以及把《公开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》中列举的非经常性损益项目界定为经常性损益的项目,应说明原因□ 适用 √ 不适用公司报告期不存在将根据《公开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》定义、列举的非经常性损益项目界定为经常性损益的项目的情形。二、报告期末股东总数及前十名股东持股情况表1、报告期末普通股股东总数及前十名普通股股东持股情况表
                                                                                                              单位:股
    报告期末普通股股东总数                                                                                         32,752
                                          前 10 名普通股股东持股情况
                                                                            持有有限售           质押或冻结情况
             股东名称                股东性质      持股比例   持股数量      条件的股份
                                                                                            股份状态         数量
                                                                               数量
    深圳市乐仁科技有限公司            境内非国有法人     36.94% 295,562,100                 0乌鲁木齐金田土股权投资合伙企业
                                  境内非国有法人     31.87% 255,025,800                 0(有限合伙)乌鲁木齐水滴石穿股权投资合伙企
                                  境内非国有法人      3.63%   29,016,000                0业(有限合伙)
    乌鲁木齐飞来石股权投资有限公司 境内非国有法人         3.15%   25,200,000                0     质押         22,100,000国联证券—上海银行—国联汇金 29
                                  其他                0.99%    7,956,128       7,956,128号集合资产管理计划宏信证券—光大银行—宏信证券多
                                  其他                0.62%    5,000,000                0赢一号集合资产管理计划
    彭坤尧                            境内自然人          0.40%    3,213,200                0中国农业银行—中邮核心优选股票
                                  其他                0.31%    2,499,942                0型证券投资基金中国工商银行—招商核心价值混合
                                  其他                0.30%    2,384,097                0型证券投资基金中国工商银行—宝盈泛沿海区域增
                                  其他                0.26%    2,045,798                0长股票证券投资基金
                                     前 10 名无限售条件普通股股东持股情况
                                                                                              股份种类
            股东名称                      持有无限售条件普通股股份数量
                                                                                      股份种类             数量
    深圳市乐仁科技有限公司                                             295,562,100 人民币普通股               295,562,100
                                                          深圳市海普瑞药业股份有限公司 2014 年第三季度报告全文乌鲁木齐金田土股权投资合伙企业
                                                                  255,025,800 人民币普通股       255,025,800(有限合伙)乌鲁木齐水滴石穿股权投资合伙企
                                                                    29,016,000 人民币普通股       29,016,000业(有限合伙)
    乌鲁木齐飞来石股权投资有限公司                                      25,200,000 人民币普通股       25,200,000宏信证券—光大银行—宏信证券多
                                                                     5,000,000 人民币普通股         5,000,000赢一号集合资产管理计划
    彭坤尧                                                               3,213,200 人民币普通股         3,213,200中国农业银行—中邮核心优选股票
                                                                     2,499,942 人民币普通股         2,499,942型证券投资基金中国工商银行—招商核心价值混合
                                                                     2,384,097 人民币普通股         2,384,097型证券投资基金中国工商银行—宝盈泛沿海区域增
                                                                     2,045,798 人民币普通股         2,045,798长股票证券投资基金
    卜湘晖                                                               1,890,020 人民币普通股         1,890,020
                                 深圳市乐仁科技有限公司和乌鲁木齐金田土股权投资合伙企业(有限合伙)的股东(合
                                 伙人)为李锂和李坦,乌鲁木齐飞来石股权投资有限公司的股东为李锂,乌鲁木齐水
                                 滴石穿股权投资合伙企业(有限合伙)的合伙人为单宇和李坦,李锂和李坦为夫妻关上述股东关联关系或一致行动的说
                                 系,单宇和李坦为兄妹关系,国联证券—上海银行—国联汇金 29 号集合资产管理计划明
                                 为公司员工持股计划,单宇参加了此计划。除上述情况外,公司未知其他前十名股东
                                 之间是否存在关联关系,也未知是否属于一致行动人;公司未知其他前十名无限售条
                                 件股东之间是否存在关联关系,也未知是否属于一致行动人。
                                 股东彭坤尧通过招商证券股份有限公司客户信用交易担保证券账户持有 3,213,200前 10 名无限售条件普通股股东参与 股,通过普通账户持有 0 股,实际合计持有 3,213,200 股;股东卜湘晖通过招商证券融资融券业务股东情况说明(如有)股份有限公司客户信用交易担保证券账户持有 1,890,020 股,通过普通账户持有 0 股,
                                 实际合计持有 1,890,020 股。公司前 10 名普通股股东、前 10 名无限售条件普通股股东在报告期内是否进行约定购回交易□ 是 √ 否公司前 10 名普通股股东、前 10 名无限售条件普通股股东在报告期内未进行约定购回交易。2、报告期末优先股股东总数及前十名优先股股东持股情况表□ 适用 √ 不适用
                                                   深圳市海普瑞药业股份有限公司 2014 年第三季度报告全文
                                    第三节 重要事项一、报告期主要会计报表项目、财务指标发生变动的情况及原因√ 适用 □ 不适用
    (一)资产负债表项目
    1.报告期末,以公允价值计量且变动计入当期损益的金融资产为 1,457,992.00 元,比年初增长了131.64%,主要原因是:报告期内远期结汇约定交割汇率与期末银行远期报价汇率差价变大所致。
    2.报告期末,应收账款为 357,040,289.77 元,比年初增长了 82.14%,主要原因是:报告期内收购 SPL,将其应收账款纳入合并范围以及母公司本季度销售收入较去年第四季度销售收入增加所致。
    3.报告期末,应收利息为 23,249,244.07 元,比年初下降了 81.58%,主要原因是:报告期内应收利息到期结算所致。
    4.报告期末,其他应收款为 11,973,944.08 元,比年初下降了 62.18%,主要原因是:报告期内应收出口退税款减少所致。
    5.报告期末,存货为 949,352,967.84 元,比年初增长了 40.13%,主要原因是:报告期内收购 SPL,将其存货纳入合并范围所致。
    6.报告期末,一年内到期的非流动资产为 0 元,比年初减少 1,000,000.00 元,主要原因是:年初持有的理财产品到期所致。
    7.报告期末,其他流动资产为 688,777,903.76 元,比年初增长了 1,277.56%,主要原因是:报告期购买理财产品所致。
    8.报告期末,可供出售金融资产为 456,282,688.11 元,比年初增长了 77.97%,主要原因是:报告期内该资产公允价值变动所致。
    9.报告期末,固定资产为 672,382,371.36 元,比年初增长了 66.86%,主要原因是:报告期内收购 SPL,将其固定资产纳入合并范围所致。
    10.报告期末,在建工程为 220,177,126.01 元,比年初增长了 67.62%,主要原因是:报告期内收购SPL,将其在建工程纳入合并范围以及子公司朋和置业和山东瑞盛工程建设投入增加所致。
    11.报告期末,开发支出为 1,077,621.91 元,比年初增长了 112.28%,主要原因是:报告期内研发投入增加所致。
      12.报告期末,商誉为 1,153,152,030.46 元,年初数为 0 元,主要原因是:报告期内收购 SPL,收购成本大于收购日可辨认净资产公允价值所致。
    13.报告期末,递延所得税资产为 32,909,462.85 元,比年初增长了 771.90%,主要原因是:报告期收购 SPL,将其递延所得税资产纳入合并范围所致。
                                                    深圳市海普瑞药业股份有限公司 2014 年第三季度报告全文
       14.报告期末,短期借款为 477,274,812.31 元,年初数为 0 元,主要原因是:报告期内子公司美国海普瑞向招商银行纽约分行借款以及收购 SPL,将其短期借款纳入合并范围所致。
       15.报告期末,预收款项为 2,252,737.21 元,比年初增长了 59.17%,主要原因是:报告期收购 SPL,将其预收款项纳入合并范围所致。
       16.报告期末,应付职工薪酬为 7,892,977.88 元,比年初减少了 67.64%,主要原因是:报告期支付海普瑞 2013 年期末计提的年终奖金以及报告期收购 SPL,将其应付职工薪酬纳入合并范围所致所致。
       17.报告期末,应付利息为 8,343,768.31 元,年初数为 0 元,主要原因是:子公司美国海普瑞向招商银行纽约分行贷款计提应付利息所致。
       18.报告期末,长期借款为 538,959,000.00 元,年初数为 0 元,主要原因是:子公司美国海普瑞向招商银行纽约分行贷款所致。
       19.报告期末,预计负债为 3,367,564.72 元,年初数为 0 元,主要原因是:报告期收购 SPL,将其预计负债纳入合并范围所致。
       20.报告期末,递延所得税负债为 135,391,692.31 元,比年初增长了 262.85%,主要原因是:报告期内收购 SPL 形成的递延所得税负债以及母公司可供出售金融资产公允价值变动影响增加递延所得税负债所致。
       21.报告期末,其他非流动负债为 63,049,105.52 元,比年初增长了 82.88%,主要原因是:报告期内收购 SPL 将其其他非流动负债纳入合并范围所致。
       22.报告期末,其他综合收益为 327,889,456.40 元,比年初增长了 101.12%,主要原因是:报告期内可供出售金融资产公允价值变动所致
       (二)利润表项目
       1.年初至报告期末,营业税金及附加为 6,350,005.05 元,比上年同期数下降 46.92%,主要原因是:报告期税基减少所致。
       2.年初至报告期末,销售费用为 9,171,030.26 元,比上年同期数增加 83.53%,主要原因是:报告期收购 SPL 公司,将其销售费用纳入合并范围所致。
       3.年初至报告期末,管理费用为 234,400,402.76 元,比上年同期数增长 63.30%,主要原因是:报告期收购 SPL 的并购费用增加以及将 SPL 的管理费用纳入合并范围所致。
       4.年初至报告期末,公允价值变动收益为 828,567.00 元,比上年同期数增长 123.23%,主要原因是:报告期远期结汇交易产生收益增加所致。
       5.年初至报告期末,投资收益为 465,206.63 元,比上年同期数增长 214.45%,主要原因是:报告期理财产品到期产生收益增加所致。
       6.年初至报告期末,营业外收入为 2,809,121.92 元,比上年同期数减少 35.60%,主要原因是:报告期政府补助收入减少所致。
       7.年初至报告期末,营业外支出为 677,353.55 元,比上年同期数增长 76.87%,主要原因是:报告期
                                                            深圳市海普瑞药业股份有限公司 2014 年第三季度报告全文收购 SPL,将其营业外支出纳入合并范围以及母公司发生对外捐赠支出所致。
    8.年初至报告期末,少数股东损益为-1,598,048.33 元,比上年同期数增加 1,439,652.30 元,主要原因是:子公司亏损减少所致。
    (三)现金流量表项目
    1.年初至报告期末,经营活动产生的现金流量净额为 721,110,135.47 元,比上年同期数增加 73.26%,主要原因是:报告期内购买原材料支付的现金减少所致。
    2.年初至报告期末,投资活动产生的现金流量净额为-2,182,146,116.11 元,比上年同期数减少1,886,560,054.00 元,主要原因是:报告期内支付购买 SPL 股权的现金所致。
    3. 年 初 至 报告 期 末 , 筹 资 活 动 产 生 的 现 金 流 量 净 额 为 57,543,861.45 元 , 比 上 年 同 期 数 增 加610,830,395.55 元,主要原因是:报告期内银行借款增加所致。
    4.年初至报告期末,汇率变动对现金及现金等价物的影响额为-6,125,617.03 元,比上年同期数减少5,689,201.55 元,主要原因是:报告期内汇率变动影响所致。
    5.年初至报告期末,现金及现金等价物净增加额报告期发生数为-1,409,617,736.22 元,比上年同期数减少 976,521,399.98 元,主要原因是:报告期内收购 SPL 和分配股利所致。二、重要事项进展情况及其影响和解决方案的分析说明√ 适用 □ 不适用
    1.为了规避和防范汇率风险,2014 年 4 月 16 日公司第二届董事会第三十一次会议审议通过了《关于开展 2014 年度远期外汇交易的议案》,同意公司以合资格的境内商业银行作为交易对手方进行远期外汇交易,自董事会审议通过之日起 12 个月内,公司进行的远期外汇交易合计不超过 10,000 万美元。
    根据公司第二届董事会第三十一次会议对 2014 年度远期外汇交易额度的批准,报告期内,已完成交割及尚未到交割时间的远期外汇交易具体情况如下:
         交易方向     委托日期      交易金额(美元)      约定交割时间       约定交割汇率         交易对象
         卖出美元    2014.05.27          1,000,000.00    2014.07.31           6.2580              招行
         卖出美元    2014.05.27          2,000,000.00    2014.08.29           6.2720              中信
         卖出美元    2014.05.27          2,000,000.00    2014.08.29           6.2735              招行
         卖出美元    2014.05.28          1,870,000.00    2014.08.29           6.2810              招行
         卖出美元    2014.06.17          1,000,000.00    2014.08.29           6.2500              工行
         卖出美元    2014.06.17          1,000,000.00    2014.08.29           6.2555              工行
         卖出美元    2014.06.17          1,000,000.00    2014.09.30           6.2610              中信
         卖出美元    2014.06.24          1,000,000.00    2014.10.31           6.2630              工行
         卖出美元    2014.06.25          1,870,000.00    2014.11.28           6.2770              工行
         卖出美元    2014.06.25          2,000,000.00    2014.11.28           6.2807              工行
                                                               深圳市海普瑞药业股份有限公司 2014 年第三季度报告全文
           卖出美元   2014.06.25         4,000,000.00        2014.11.28        6.2810               招行
           卖出美元   2014.06.25         1,000,000.00        2014.12.31        6.2830               中信
           卖出美元   2014.06.25         5,000,000.00        2015.01.30        6.2895               招行
    2.公司于 2014 年 7 月 9 日召开第三届董事会第三次会议审议通过了《关于公司员工借款实施员工持股计划的议案》,并于 2014 年 7 月 28 日经公司 2014 年第二次临时股东大会审议通过。该员工持股计划已完成,共计购买 7,956,128 股公司股票,占公司总股本的比例为 0.99%。
              重要事项概述                            披露日期                      临时报告披露网站查询索引
                                                                               公告编号:2014-060;公告名称:《关
                                                                               于公司员工持股计划完成股票购买的
                                                                               公告》;公告刊登媒体:《证券时报》、
                                       2014 年 09 月 23 日
                                                                               《中国证券报》、《上海证券报》、《证
                                                                               券日报》和巨潮资讯网
                                                                               (http://www.cninfo.com.cn)
                                                                               公告编号:2014-058;公告名称:《关
                                                                               于公司员工持股计划实施的进展公
                                                                               告》;公告刊登媒体:《证券时报》、
                                       2014 年 08 月 28 日
                                                                               《中国证券报》、《上海证券报》、《证
                                                                               券日报》和巨潮资讯网
    关于公司员工持股计划的相关事项                                                 (http://www.cninfo.com.cn)
                                                                               公告编号:2014-048;公告名称:《2014
                                                                               年第二次临时股东大会决议公告 》;
                                                                               公告刊登媒体:《证券时报》、《中国
                                       2014 年 07 月 28 日
                                                                               证券报》、《上海证券报》、《证券日
                                                                               报》和巨潮资讯网
                                                                               (http://www.cninfo.com.cn)
                                                                               公告编号:2014-045;公告名称:《员
                                                                               工持股计划(草案)摘要》;公告刊登
                                       2014 年 07 月 10 日                     媒体:《证券时报》、《中国证券报》、
                                                                               《上海证券报》、《证券日报》和巨潮
                                                                               资讯网(http://www.cninfo.com.cn)三、公司或持股 5%以上股东在报告期内发生或以前期间发生但持续到报告期内的承诺事项√ 适用 □ 不适用
           承诺事由           承诺方                     承诺内容                    承诺时间     承诺期限 履行情况
    股改承诺                     不适用    不适用                                                     不适用      不适用收购报告书或权益变动报告书 不适用
                                       不适用                                                     不适用      不适用中所作承诺
    资产重组时所作承诺           不适用    不适用                                                     不适用      不适用
                                                           深圳市海普瑞药业股份有限公司 2014 年第三季度报告全文首次公开发行或再融资时所作
                             不适用   不适用                                                不适用   不适用承诺
                                      (一)关于避免同业竞争的承诺:公司股东深
                                      圳市乐仁科技有限公司、深圳市金田土科技
                                      有限公司和深圳市飞来石科技有限公司承
                                      诺:1、在本公司作为公司控股股东期间,本
                                      公司保证不自营或以合资、合作等方式经营
                                      任何与公司现从事的业务有竞争的业务,本
                                      公司现有的或将来成立的全资子公司、控股
                                      子公司以及其他受本公司控制的企业亦不会
                                      经营与公司现从事的业务有竞争的业务。2、
                                      如违反上述承诺,本公司同意承担给公司造
                             公司股东 成的全部损失。(二)关于税收事项的承诺:1、
                             深圳市乐 公司股东深圳市乐仁科技有限公司和深圳市
                             仁科技有 金田土科技有限公司承诺:如今后公司或子
                             限公司、 公司深圳市多普生生物技术有限公司因依据
                             乌鲁木齐 深府[1988]232 号文享受的企业所得税优惠
                                                                                                     报告期
                             金田土股 被税务机关撤消而产生的额外税项和费用
                                                                                                     内,承诺
                             权投资合 时,将及时、无条件、全额返还公司或深圳
    其他对公司中小股东所作承诺                                                                           人严格履
                             伙企业   市多普生生物技术有限公司补缴的税款以及
                                                                                                     行了上述
                             (有限合 因此所产生的所有相关费用。2、公司股东深
                                                                                                     承诺。
                             伙)和乌 圳市乐仁科技有限公司和深圳市金田土科技
                             鲁木齐飞 有限公司承诺:如今后公司因以实际缴纳的
                             来石股权 增值税和营业税税额为计税依据缴纳城市维
                             投资有限 护建设税和教育费附加事宜被税务机关追缴
                             公司     而产生额外税项和费用时,将及时、无条件、
                                      全额返还公司补缴的税款以及因此所产生的
                                      所有相关费用。(三)关于住房公积金事项
                                      的承诺:公司股东深圳市乐仁科技有限公司和
                                      深圳市金田土科技有限公司承诺:如今后公
                                      司或子公司深圳市多普生生物技术有限公司
                                      因上市前执行住房公积金政策事宜被要求补
                                      缴住房公积金、缴纳罚款或因此遭受任何损
                                      失时,将及时、无条件、全额返还公司或深
                                      圳市多普生生物技术有限公司由此遭受的一
                                      切损失。
    承诺是否及时履行             是未完成履行的具体原因及下一
                             无步计划(如有)四、对 2014 年度经营业绩的预计2014 年度预计的经营业绩情况:归属于上市公司股东的净利润为正值且不属于扭亏为盈的情形
                                                            深圳市海普瑞药业股份有限公司 2014 年第三季度报告全文归属于上市公司股东的净利润为正值且不属于扭亏为盈的情形2014 年度归属于上市公司股东的净利润变动幅
                                                                   -15.00%      至                         15.00%度2014 年度归属于上市公司股东的净利润变动区
                                                                  26,973.46     至                        36,493.5间(万元)
    2013 年度归属于上市公司股东的净利润(万元)                                                              31,733.48
                                                   报告期内,公司将SPL纳入合并报表范围,营业收入较上年增业绩变动的原因说明
                                             加;但同时支付收购SPL的中介机构费用,导致管理费用大幅增加。五、证券投资情况√ 适用 □ 不适用
                             最初投资 期初持股 期初持股 期末持股 期末持股 期末账面 报告期损 会计核算 股份来证券品种 证券代码 证券简称
                             成本(元)数量(股) 比例    数量(股) 比例     值(元) 益(元)   科目      源
                                                                                                         根据雇
                                                                                                         主养老
                             22,200,3                                         33,622,8 7,288,20          金计划
    基金        BMBQX BMBQX
                                 51.21                                           77.11     8.92          提取的
                                                                                                         养老金
                                                                                                         购买
                             22,200,3                                         33,622,8 7,288,20
    合计                                                 --               --                           --        --
                                 51.21                                           77.11     8.92证券投资审批董事会公告披露
                             2014 年 08 月 28 日日期证券投资审批股东会公告披露
                             2014 年 09 月 24 日日期
       公司收购的 SPL 于 2004 年 2 月 10 日经其董事会审议后开始启动雇主养老金计划,并于 2005 年 1 月 1日正式实施。根据《雇员退休收入保障法案》,2014 年 SPL 可用于投资的养老金金额为 90.7 万美元,分五次提取后交由雇主养老金计划进行投资管理。报告期内,截至 2014 年 9 月 30 日雇主养老金计划累计投资账户余额为 2,633.47 万元人民币(428.03 万美元,根据 2014 年 9 月 30 日的人民币汇率计算),市场公允价值为 3,362.29 万元人民币(546.49 万美元,根据 2014 年 9 月 30 日的人民币汇率计算)。持有其他上市公司股权情况的说明√ 适用 □ 不适用
       2012 年 10 月 15 日公司第二届董事会第十九次会议、第二届监事会第十七次会议审议通过了《关于对外投资的议案》,同意公司使用自有资金 9,999,999 美元参与认购 Prometic Life Sciences Inc.增发的48,147,053 股股票,占增发后总股本的 10.02%,获配的股票自 PLI 本次发行结束之日起三年零一天不出售不转让。公司购买成本为人民币 62,160,000.00 元,截止到 2014 年 9 月 30 日,公允价值变动金额394,122,688.11 元。
                                                  深圳市海普瑞药业股份有限公司 2014 年第三季度报告全文六、新颁布或修订的会计准则对公司合并财务报表的影响√ 适用 □ 不适用
    1.执行《企业会计准则第 30 号—财务报表列报(2014 年修订)》情况
    根据《企业会计准则第 30 号—财务报表列报(2014 年修订)》对其他综合收益项目列报的相关修订要求,在资产负债表中所有者权益类增加“其他综合收益”项目,核算根据其他会计准则规定未在当期损益中确认的各项利得和损失,在利润表中,应将其他综合收益项目划分为两类:(1)后续不会重分类至损益的项目;(2)在满足特定条件的情况下,后续可能重分类至损益的项目。根据此规定,公司将外币财务报表折算差额、原列入“资本公积”中可供出售金融资产公允价值变动重分类至“其他综合收益”,并进行了追溯调整,调整事项对 2013 年度合并资产负债表的影响如下表:
                                                                                    调整后金额(元)
          调整事项           报表科目        调整前金额(元)       调整数(元)
         将“其他综合收       资本公积         5,487,170,726.29   -165,093,159.12   5,322,077,567.17
    益”作为会计报表项目      其他综合收益                      -   163,034,465.71      163,034,465.71
    在资产负债表中单独
                          外币报表折算差额        -2,058,693.41     2,058,693.41                   -
             列示
    调整事项对 2013 年度母公司合并资产负债表的影响如下表:
                                                                                    调整后金额(元)
          调整事项           报表科目        调整前金额(元)       调整数(元)
         将“其他综合收       资本公积         5,493,328,592.10   -165,093,159.12   5,328,235,432.98
    益”作为会计报表项目      其他综合收益                      -   165,093,159.12      165,093,159.12
    在资产负债表中单独
                          外币报表折算差额                    0                0                   -
             列示
    上述会计政策变更,仅对其他综合收益、资本公积、外币报表折算差额三个报表项目金额产生影响,对公司 2013 年度总资产、负债总额、净资产及净利润不产生任何影响。
    2. 执行《企业会计准则第 2 号—长期股权投资》、《企业会计准则第 9 号—职工薪酬》、《企业会计准则第 33 号——合并财务报表》、《企业会计准则第 37 号—金融工具列报》、《企业会计准则第 39号-公允价值计量》、《企业会计准则第 40 号-合营安排》、《企业会计准则第 41 号-在其他主体中权益的披露》的相关情况
    公司本期财务报表中关于长期股权投资、职工薪酬、合并财务报表、金融工具列报、公允价值计量、合营安排及与在其他主体中权益的相关业务及事项,已按上述准则的规定进行核算与披露,新准则的实施不会对公司财务报表产生影响。
                                                       深圳市海普瑞药业股份有限公司 2014 年第三季度报告全文
                                         第四节 财务报表一、财务报表1、合并资产负债表编制单位:深圳市海普瑞药业股份有限公司
                                                                                                     单位:元
                 项目                       期末余额                               期初余额流动资产:
    货币资金                                      4,640,657,877.86                        6,050,275,614.08
    结算备付金
    拆出资金
    以公允价值计量且其变动计入当
                                                         1,457,992.00                            629,425.00期损益的金融资产
    应收票据
    应收账款                                           357,040,289.77                         196,025,543.07
    预付款项                                            47,284,054.13                          44,849,969.11
    应收保费
    应收分保账款
    应收分保合同准备金
    应收利息                                            23,249,244.07                         126,211,897.32
    应收股利
    其他应收款                                          11,973,944.08                          31,658,182.17
    买入返售金融资产
    存货                                               949,352,967.84                         677,466,001.34
    划分为持有待售的资产
    一年内到期的非流动资产                                       0.00                           1,000,000.00
    其他流动资产                                       688,777,903.76                          50,000,000.00
    流动资产合计                                      6,719,794,273.51                        7,178,116,632.09非流动资产:
    发放委托贷款及垫款
    可供出售金融资产                                   456,282,688.11                         256,387,246.02
    持有至到期投资
                                     深圳市海普瑞药业股份有限公司 2014 年第三季度报告全文
    长期应收款
    长期股权投资
    投资性房地产
    固定资产                        672,382,371.36                       402,959,158.39
    在建工程                        220,177,126.01                       131,355,858.97
    工程物资
    固定资产清理
    生产性生物资产
    油气资产
    无形资产                        173,833,249.18                       176,992,970.88
    开发支出                           1,077,621.91                          507,640.11
    商誉                           1,153,152,030.46
    长期待摊费用                     91,820,168.18                        95,514,123.86
    递延所得税资产                   32,909,462.85                          3,774,466.70
    其他非流动资产                   28,035,323.51                        25,771,107.48
    非流动资产合计                     2,829,670,041.57                     1,093,262,572.41
    资产总计                           9,549,464,315.08                     8,271,379,204.50流动负债:
    短期借款                        477,274,812.31                                  0.00
    向中央银行借款
    吸收存款及同业存放
    拆入资金
    以公允价值计量且其变动计入当期损益的金融负债
    应付票据                            198,634.20                           262,551.87
    应付账款                         57,518,218.31                        72,598,338.82
    预收款项                           2,252,737.21                         1,415,344.14
    卖出回购金融资产款
    应付手续费及佣金
    应付职工薪酬                       7,892,977.88                       24,387,434.64
    应交税费                         30,670,183.02                        27,352,235.36
    应付利息                           8,343,768.31                                 0.00
    应付股利
    其他应付款                         5,492,458.28                         6,000,909.41
                                                    深圳市海普瑞药业股份有限公司 2014 年第三季度报告全文
    应付分保账款
    保险合同准备金
    代理买卖证券款
    代理承销证券款
    划分为持有待售的负债
    一年内到期的非流动负债
    其他流动负债
    流动负债合计                                       589,643,789.52                       132,016,814.24非流动负债:
    长期借款                                      538,959,000.00
    应付债券
    长期应付款
    专项应付款
    预计负债                                        3,367,564.72
    递延所得税负债                                135,391,692.31                        37,312,915.82
    其他非流动负债                                 63,049,105.52                        34,474,848.14
    非流动负债合计                                     740,767,362.55                        71,787,763.96
    负债合计                                         1,330,411,152.07                       203,804,578.20所有者权益(或股东权益):
    实收资本(或股本)                            800,200,000.00                       800,200,000.00
    资本公积                                    5,322,077,567.17                      5,322,077,567.17
    减:库存股
    专项储备
    其他综合收益                                  327,889,456.40                       163,034,465.71
    盈余公积                                      394,749,608.89                       394,749,608.89
    一般风险准备
    未分配利润                                  1,290,016,344.80                      1,305,994,750.45
    归属于母公司所有者权益合计                       8,134,932,977.26                      7,986,056,392.22
    少数股东权益                                   84,120,185.75                        81,518,234.08
    所有者权益(或股东权益)合计                     8,219,053,163.01                      8,067,574,626.30负债和所有者权益(或股东权益)总
                                                 9,549,464,315.08                      8,271,379,204.50计
    法定代表人:李锂                   主管会计工作负责人:孔芸                       会计机构负责人:孔芸
                                                    深圳市海普瑞药业股份有限公司 2014 年第三季度报告全文2、母公司资产负债表编制单位:深圳市海普瑞药业股份有限公司
                                                                                                  单位:元
                 项目                    期末余额                               期初余额流动资产:
    货币资金                                   4,437,776,418.89                        5,691,005,685.12
    以公允价值计量且其变动计入当
                                                      1,457,992.00                            629,425.00期损益的金融资产
    应收票据
    应收账款                                        327,796,932.26                         201,046,399.37
    预付款项                                         37,614,325.72                          50,829,417.52
    应收利息                                         40,031,811.47                         124,055,200.58
    应收股利
    其他应收款                                       60,085,178.59                          72,710,918.34
    存货                                            361,880,095.10                         672,552,879.23
    划分为持有待售的资产
    一年内到期的非流动资产
    其他流动资产                                    690,300,000.00                         160,000,000.00
    流动资产合计                                   5,956,942,754.03                        6,972,829,925.16非流动资产:
    可供出售金融资产                                456,282,688.11                         256,387,246.02
    持有至到期投资
    长期应收款                                      451,901,125.00
    长期股权投资                               1,276,012,419.70                            589,322,508.99
    投资性房地产
    固定资产                                        231,731,842.07                         238,171,363.98
    在建工程                                          9,831,409.51                           4,413,199.11
    工程物资
    固定资产清理
    生产性生物资产
    油气资产
    无形资产                                        111,458,575.28                         112,737,067.08
    开发支出                                           327,008.04                             153,804.44
    商誉
                                     深圳市海普瑞药业股份有限公司 2014 年第三季度报告全文
    长期待摊费用                     88,743,941.57                        92,293,699.25
    递延所得税资产                      506,706.35                          3,774,466.70
    其他非流动资产                   24,276,679.97                        24,431,635.76
    非流动资产合计                     2,651,072,395.60                     1,321,684,991.33
    资产总计                           8,608,015,149.63                     8,294,514,916.49流动负债:
    短期借款
    以公允价值计量且其变动计入当期损益的金融负债
    应付票据
    应付账款                         23,448,531.77                        53,573,648.65
    预收款项                             96,939.16                           565,926.45
    应付职工薪酬                        361,303.33                        22,624,455.10
    应交税费                         29,193,686.97                        32,759,525.08
    应付利息
    应付股利
    其他应付款                      112,446,803.96                          4,382,611.73
    划分为持有待售的负债
    一年内到期的非流动负债
    其他流动负债
    流动负债合计                        165,547,265.19                       113,906,167.01非流动负债:
    长期借款
    应付债券
    长期应付款
    专项应付款
    预计负债
    递延所得税负债                   59,222,254.55                        29,228,500.65
    其他非流动负债                   27,062,694.00                        23,291,766.82
    非流动负债合计                       86,284,948.55                        52,520,267.47
    负债合计                            251,832,213.74                       166,426,434.48所有者权益(或股东权益):
    实收资本(或股本)              800,200,000.00                       800,200,000.00
    资本公积                       5,328,235,432.98                     5,328,235,432.98
                                                            深圳市海普瑞药业股份有限公司 2014 年第三季度报告全文
    减:库存股
    专项储备
    其他综合收益                                           335,004,284.89                         165,093,159.12
    盈余公积                                               394,749,608.89                         394,749,608.89
    一般风险准备
    未分配利润                                        1,497,993,609.13                        1,439,810,281.02
    所有者权益(或股东权益)合计                           8,356,182,935.89                        8,128,088,482.01负债和所有者权益(或股东权益)总
                                                       8,608,015,149.63                        8,294,514,916.49计
    法定代表人:李锂                         主管会计工作负责人:孔芸                         会计机构负责人:孔芸3、合并本报告期利润表编制单位:深圳市海普瑞药业股份有限公司
                                                                                                          单位:元
                  项目                           本期金额                               上期金额
    一、营业总收入                                               523,698,923.89                         282,665,099.00
    其中:营业收入                                          523,698,923.89                         282,665,099.00
           利息收入
           已赚保费
           手续费及佣金收入
    二、营业总成本                                               387,893,029.44                         231,270,213.96
    其中:营业成本                                          327,468,075.82                         220,891,653.86
           利息支出
           手续费及佣金支出
           退保金
           赔付支出净额
           提取保险合同准备金净额
           保单红利支出
           分保费用
           营业税金及附加                                      3,336,054.32                           2,302,829.45
           销售费用                                            4,852,275.22                           1,049,398.58
           管理费用                                           67,683,298.74                          65,018,096.54
           财务费用                                          -32,488,136.57                         -58,118,438.66
           资产减值损失                                       17,041,461.91                            126,674.19
                                                         深圳市海普瑞药业股份有限公司 2014 年第三季度报告全文
    加    :公允价值变动收益(损失
                                                             765,649.78                           894,607.60以“-”号填列)
            投资收益(损失以“-”号
                                                              22,472.40                           147,945.21填列)
            其中:对联营企业和合营企业的投资收益
            汇兑收益(损失以“-”号填列)
    三、营业利润(亏损以“-”号填列)                       136,594,016.63                         52,437,437.85
    加   :营业外收入                                       721,684.83                          2,301,558.57
    减   :营业外支出                                       416,885.42                             39,489.58
            其中:非流动资产处置损
                                                             359,343.94                             36,020.76失四、利润总额(亏损总额以“-”号填
                                                         136,898,816.04                         54,699,506.84列)
    减:所得税费用                                       23,635,249.60                         14,357,088.16
    五、净利润(净亏损以“-”号填列)                       113,263,566.44                         40,342,418.68
    其中:被合并方在合并前实现的净利润
    归属于母公司所有者的净利润                          114,051,103.59                         41,314,019.17
    少数股东损益                                           -787,537.15                           -971,600.49
    六、每股收益:                                     --                                   --
    (一)基本每股收益                                            0.14                                  0.05
    (二)稀释每股收益                                            0.14                                  0.05
    七、其他综合收益                                         132,792,984.64                        106,840,985.22其中:以后会计期间不能重分类进损益的其他综合收益项目
       以后会计期间在满足规定条件
    时将重分类进损益的其他综合收益项                         132,792,984.64                        106,840,985.22目
    八、综合收益总额                                         246,056,551.08                        147,183,403.90
    归属于母公司所有者的综合收益
                                                         246,844,088.23                        148,155,004.39总额
    归属于少数股东的综合收益总额                           -787,537.15                           -971,600.49
    法定代表人:李锂                        主管会计工作负责人:孔芸                       会计机构负责人:孔芸
                                                    深圳市海普瑞药业股份有限公司 2014 年第三季度报告全文4、母公司本报告期利润表编制单位:深圳市海普瑞药业股份有限公司
                                                                                                 单位:元
                 项目                    本期金额                               上期金额
    一、营业收入                                        396,577,170.64                         274,475,556.57
    减:营业成本                                   253,682,274.36                         213,110,244.98
         营业税金及附加                               3,307,830.32                           2,274,605.45
         销售费用                                     1,582,477.10                            913,972.18
         管理费用                                    30,432,594.69                          46,876,344.06
         财务费用                                    -51,289,085.35                        -56,558,343.40
         资产减值损失                                                                         126,674.19
    加:公允价值变动收益(损失以
                                                        765,649.78                            894,607.60“-”号填列)
         投资收益(损失以“-”号填
                                                      1,746,800.00                           1,913,195.21列)
         其中:对联营企业和合营企业的投资收益
    二、营业利润(亏损以“-”号填列)                  161,373,529.30                          70,539,861.92
    加:营业外收入                                     282,213.38                           2,134,811.50
    减:营业外支出                                      32,545.67                              36,020.76
         其中:非流动资产处置损失                        32,545.67                              36,020.76三、利润总额(亏损总额以“-”号填
                                                    161,623,197.01                          72,638,652.66列)
    减:所得税费用                                  24,243,479.55                          14,463,042.61
    四、净利润(净亏损以“-”号填列)                  137,379,717.46                          58,175,610.05
    五、每股收益:                              --                                     --
    (一)基本每股收益                                       0.17                                   0.07
    (二)稀释每股收益                                       0.17                                   0.07
    六、其他综合收益                                    132,873,964.33                         107,103,392.61其中:以后会计期间不能重分类进损益的其他综合收益项目
       以后会计期间在满足规定条件
    时将重分类进损益的其他综合收益项                    132,873,964.33                         107,103,392.61目
    七、综合收益总额                                    270,253,681.79                         165,279,002.66
                                                            深圳市海普瑞药业股份有限公司 2014 年第三季度报告全文
    法定代表人:李锂                         主管会计工作负责人:孔芸                         会计机构负责人:孔芸5、合并年初到报告期末利润表编制单位:深圳市海普瑞药业股份有限公司
                                                                                                          单位:元
                   项目                          本期金额                               上期金额
    一、营业总收入                                         1,434,840,528.99                        1,229,515,371.97
    其中:营业收入                                     1,434,840,528.99                        1,229,515,371.97
           利息收入
           已赚保费
           手续费及佣金收入
    二、营业总成本                                         1,152,529,853.93                            882,848,133.83
    其中:营业成本                                     1,020,514,149.69                            889,056,017.06
           利息支出
           手续费及佣金支出
           退保金
           赔付支出净额
           提取保险合同准备金净额
           保单红利支出
           分保费用
           营业税金及附加                                     6,350,005.05                          11,964,048.54
           销售费用                                           9,171,030.26                           4,996,956.80
           管理费用                                         234,400,402.76                         143,542,344.98
           财务费用                                     -120,780,148.87                         -169,312,392.91
           资产减值损失                                       2,874,415.04                           2,601,159.36
    加   :公允价值变动收益(损失
                                                               828,567.00                             371,170.00以“-”号填列)
           投资收益(损失以“-”号
                                                               465,206.63                             147,945.21填列)
           其中:对联营企业和合营企业的投资收益
           汇兑收益(损失以“-”号填列)
    三、营业利润(亏损以“-”号填列)                          283,604,448.69                         347,186,353.35
    加   :营业外收入                                         2,809,121.92                           4,362,114.40
                                                            深圳市海普瑞药业股份有限公司 2014 年第三季度报告全文
    减   :营业外支出                                         677,353.55                             382,959.11
            其中:非流动资产处置损
                                                               442,025.86                             374,945.03失四、利润总额(亏损总额以“-”号填
                                                            285,736,217.06                         351,165,508.64列)
    减:所得税费用                                          63,252,671.04                          62,623,538.01
    五、净利润(净亏损以“-”号填列)                          222,483,546.02                         288,541,970.63
    其中:被合并方在合并前实现的净利润
    归属于母公司所有者的净利润                             224,081,594.35                         291,579,671.26
    少数股东损益                                            -1,598,048.33                          -3,037,700.63
    六、每股收益:                                      --                                     --
    (一)基本每股收益                                               0.28                                   0.36
    (二)稀释每股收益                                               0.28                                   0.36
    七、其他综合收益                                            164,854,990.69                         131,214,755.31其中:以后会计期间不能重分类进损益的其他综合收益项目
       以后会计期间在满足规定条件
    时将重分类进损益的其他综合收益项                            164,854,990.69                         131,214,755.31目
    八、综合收益总额                                            387,338,536.71                         419,756,725.94
    归属于母公司所有者的综合收益
                                                            388,936,585.04                         422,794,426.57总额
    归属于少数股东的综合收益总额                            -1,598,048.33                          -3,037,700.63
    法定代表人:李锂                         主管会计工作负责人:孔芸                         会计机构负责人:孔芸6、母公司年初到报告期末利润表编制单位:深圳市海普瑞药业股份有限公司
                                                                                                          单位:元
                 项目                            本期金额                               上期金额
    一、营业收入                                             1,017,139,622.80                       1,214,137,273.40
    减:营业成本                                           736,909,472.99                         868,539,930.79
          营业税金及附加                                      6,265,333.05                          11,859,720.54
          销售费用                                            2,618,161.65                           4,154,759.85
          管理费用                                           87,909,820.54                          97,647,138.14
                                                            深圳市海普瑞药业股份有限公司 2014 年第三季度报告全文
         财务费用                                         -157,887,425.09                        -165,263,469.16
         资产减值损失                                          713,436.13                             794,612.89
    加:公允价值变动收益(损失以
                                                               828,567.00                             371,170.00“-”号填列)
         投资收益(损失以“-”号填
                                                              5,686,596.23                           5,536,756.32列)
         其中:对联营企业和合营企业的投资收益
    二、营业利润(亏损以“-”号填列)                          347,125,986.76                         402,312,506.67
    加:营业外收入                                           1,728,719.24                           2,490,748.29
    减:营业外支出                                            263,755.64                               38,856.67
         其中:非流动资产处置损失                              113,755.64                               38,856.67三、利润总额(亏损总额以“-”号填
                                                            348,590,950.36                         404,764,398.29列)
    减:所得税费用                                          50,347,622.25                          62,941,364.30
    四、净利润(净亏损以“-”号填列)                          298,243,328.11                         341,823,033.99
    五、每股收益:                                      --                                     --
    (一)基本每股收益                                               0.37                                   0.43
    (二)稀释每股收益                                               0.37                                   0.43
    六、其他综合收益                                            169,911,125.77                         132,609,394.47其中:以后会计期间不能重分类进损益的其他综合收益项目
       以后会计期间在满足规定条件
    时将重分类进损益的其他综合收益项                            169,911,125.77                         132,609,394.47目
    七、综合收益总额                                            468,154,453.88                         474,432,428.46
    法定代表人:李锂                         主管会计工作负责人:孔芸                         会计机构负责人:孔芸7、合并年初到报告期末现金流量表编制单位:深圳市海普瑞药业股份有限公司
                                                                                                          单位:元
                 项目                            本期金额                               上期金额一、经营活动产生的现金流量:
    销售商品、提供劳务收到的现金                        1,538,182,499.59                       1,419,339,588.39
    客户存款和同业存放款项净增加
                                      深圳市海普瑞药业股份有限公司 2014 年第三季度报告全文额
    向中央银行借款净增加额
    向其他金融机构拆入资金净增加额
    收到原保险合同保费取得的现金
    收到再保险业务现金净额
    保户储金及投资款净增加额
    处置交易性金融资产净增加额
    收取利息、手续费及佣金的现金
    拆入资金净增加额
    回购业务资金净增加额
    收到的税费返还                   57,073,955.39                       181,510,888.26
    收到其他与经营活动有关的现金    272,942,988.76                       182,223,053.52
    经营活动现金流入小计                1,868,199,443.74                     1,783,073,530.17
    购买商品、接受劳务支付的现金    775,385,751.34                      1,113,538,879.35
    客户贷款及垫款净增加额
    存放中央银行和同业款项净增加额
    支付原保险合同赔付款项的现金
    支付利息、手续费及佣金的现金
    支付保单红利的现金
    支付给职工以及为职工支付的现
                                     172,846,495.35                       120,131,521.13金
    支付的各项税费                   53,463,471.46                        75,888,966.58
    支付其他与经营活动有关的现金    145,393,590.12                        57,301,487.66
    经营活动现金流出小计                1,147,089,308.27                     1,366,860,854.72
    经营活动产生的现金流量净额           721,110,135.47                       416,212,675.45二、投资活动产生的现金流量:
    收回投资收到的现金               80,200,000.00                        30,000,000.00
    取得投资收益所收到的现金            465,206.63                           147,945.21
    处置固定资产、无形资产和其他
                                         155,220.86                            25,845.00长期资产收回的现金净额
    处置子公司及其他营业单位收到的现金净额
    收到其他与投资活动有关的现金       3,075,081.45
                                                          深圳市海普瑞药业股份有限公司 2014 年第三季度报告全文
    投资活动现金流入小计                                      83,895,508.94                        30,173,790.21
    购建固定资产、无形资产和其他
                                                         120,968,553.82                       233,599,852.32长期资产支付的现金
    投资支付的现金                                       769,140,000.00                        92,160,000.00
    质押贷款净增加额
    取得子公司及其他营业单位支付
                                                       1,372,855,416.60                                  0.00的现金净额
    支付其他与投资活动有关的现金                           3,077,654.63                                  0.00
    投资活动现金流出小计                                   2,266,041,625.05                       325,759,852.32
    投资活动产生的现金流量净额                             -2,182,146,116.11                      -295,586,062.11三、筹资活动产生的现金流量:
    吸收投资收到的现金                                    64,200,000.00                                  0.00
    其中:子公司吸收少数股东投资
                                                           4,200,000.00                                  0.00收到的现金
    取得借款收到的现金                                 1,018,777,578.81                        76,515,224.00
    发行债券收到的现金
    收到其他与筹资活动有关的现金
    筹资活动现金流入小计                                   1,082,977,578.81                        76,515,224.00
    偿还债务支付的现金                                   766,348,510.10                       149,614,678.16
    分配股利、利润或偿付利息支付
                                                         259,085,207.26                       480,187,079.94的现金
    其中:子公司支付给少数股东的股利、利润
    支付其他与筹资活动有关的现金
    筹资活动现金流出小计                                   1,025,433,717.36                       629,801,758.10
    筹资活动产生的现金流量净额                                57,543,861.45                       -553,286,534.10四、汇率变动对现金及现金等价物的
                                                           -6,125,617.03                          -436,415.48影响
    五、现金及现金等价物净增加额                           -1,409,617,736.22                      -433,096,336.24
    加:期初现金及现金等价物余额                       6,050,275,614.08                      6,588,480,677.31
    六、期末现金及现金等价物余额                           4,640,657,877.86                      6,155,384,341.07
    法定代表人:李锂                         主管会计工作负责人:孔芸                       会计机构负责人:孔芸8、母公司年初到报告期末现金流量表编制单位:深圳市海普瑞药业股份有限公司
                                               深圳市海普瑞药业股份有限公司 2014 年第三季度报告全文
                                                                                             单位:元
               项目                 本期金额                               上期金额一、经营活动产生的现金流量:
    销售商品、提供劳务收到的现金              923,782,574.38                     1,395,038,811.21
    收到的税费返还                             57,038,651.16                         181,510,888.26
    收到其他与经营活动有关的现金              386,376,712.61                         179,581,328.71
    经营活动现金流入小计                      1,367,197,938.15                        1,756,131,028.18
    购买商品、接受劳务支付的现金              452,434,029.98                     1,107,595,022.56
    支付给职工以及为职工支付的现
                                                98,945,445.35                          92,753,050.90金
    支付的各项税费                             52,433,091.58                          74,832,947.33
    支付其他与经营活动有关的现金               66,218,930.01                          44,979,930.95
    经营活动现金流出小计                           670,031,496.92                     1,320,160,951.74
    经营活动产生的现金流量净额                     697,166,441.23                         435,970,076.44二、投资活动产生的现金流量:
    收回投资收到的现金                        162,000,000.00                         140,000,000.00
    取得投资收益所收到的现金                    5,686,596.23                           5,536,756.32
    处置固定资产、无形资产和其他
                                                    56,319.40                              15,445.00长期资产收回的现金净额
    处置子公司及其他营业单位收到的现金净额
    收到其他与投资活动有关的现金
    投资活动现金流入小计                           167,742,915.63                         145,552,201.32
    购建固定资产、无形资产和其他
                                                49,360,079.51                         177,475,046.24长期资产支付的现金
    投资支付的现金                       1,828,905,725.71                            407,160,000.00
    取得子公司及其他营业单位支付的现金净额
    支付其他与投资活动有关的现金
    投资活动现金流出小计                      1,878,265,805.22                            584,635,046.24
    投资活动产生的现金流量净额               -1,710,522,889.59                         -439,082,844.92三、筹资活动产生的现金流量:
    吸收投资收到的现金
    取得借款收到的现金                                                                76,515,224.00
    发行债券收到的现金
                                                     深圳市海普瑞药业股份有限公司 2014 年第三季度报告全文
    收到其他与筹资活动有关的现金
    筹资活动现金流入小计                                                                       76,515,224.00
    偿还债务支付的现金                                                                   149,614,678.16
    分配股利、利润或偿付利息支付
                                                    240,059,989.20                        480,187,079.94的现金
    支付其他与筹资活动有关的现金
    筹资活动现金流出小计                                240,059,989.20                        629,801,758.10
    筹资活动产生的现金流量净额                         -240,059,989.20                       -553,286,534.10四、汇率变动对现金及现金等价物的
                                                        187,171.33                           -248,976.49影响
    五、现金及现金等价物净增加额                      -1,253,229,266.23                      -556,648,279.07
    加:期初现金及现金等价物余额                 5,691,005,685.12                      6,333,271,651.85
    六、期末现金及现金等价物余额                      4,437,776,418.89                      5,776,623,372.78
    法定代表人:李锂                    主管会计工作负责人:孔芸                       会计机构负责人:孔芸二、审计报告第三季度报告是否经过审计□ 是 √ 否公司第三季度报告未经审计。
                                                                       深圳市海普瑞药业股份有限公司
                                                                           法定代表人:
                                                                                            李锂
                                                                                     2014年10月28日
数据加载中...
prevnext
手机查看股票